Search Bar & Filters
Found 190 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of the drug cemiplimab as adjuvant immunotherapy for patients with stage II-IIIA non-small cell lung cancer NSCLC who have had their tumors surgically removed and who have not received prior chemotherapy. This phase III trial focuses on comparing cemiplimab treatment to observation alone, specifically in patients whose tumors show PD-L1 expression of 1% or higher. The main goal is to measure disease-free survival, which means the time patients remain free from cancer recurrence or death. Participants in the experimental group receive cemiplimab intravenously at 350 mg every 3 weeks for 4 cycles, followed by 700 mg every 6 weeks for up to 6 cycles or until cancer returns or unacceptable side effects occur. Another group is assigned to observation without additional treatment. The study treatment schedules include specific dosing intervals and duration, designed to monitor the impact of cemiplimab on preventing cancer recurrence after surgery. Throughout the trial, participants will be monitored regularly for disease recurrence and side effects. Assessments include tracking disease-free survival and overall survival for up to approximately 59 months from randomization. Safety will be evaluated by documenting adverse events from the time of informed consent until the trial ends. Participants must comply with scheduled visits and testing to help researchers collect information on treatment effects and safety over the long term.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are studying ASTX030, a combination of azacitidine and cedazuridine, alone or with venetoclax in people with myeloid neoplasms including myelodysplastic syndromes MDS, chronic myelomonocytic leukemia CMML, and acute myeloid leukemia AML. This multi-phase study includes phases 1 through 3 for monotherapy and phases 1 and 2 for combination therapy, aiming to evaluate the safety, pharmacokinetics, and effectiveness of these treatments over approximately 8 years. Participants receive various treatments depending on the study phase and arm. Treatments include oral doses of azacitidine, cedazuridine, ASTX030, subcutaneous azacitidine, and venetoclax in different sequences and cycles, typically lasting 28 days each. Some phases involve dose escalation and expansion stages, while others compare oral and subcutaneous forms or combine ASTX030 with venetoclax. Participants in certain arms may cross over to other treatments later in the study. During the study, participants undergo regular assessments including blood tests to measure drug levels, DNA methylation, and response rates such as complete remission. Researchers track adverse events, survival outcomes, transfusion independence, and pharmacokinetics up to 36 months or longer depending on the phase. Safety monitoring includes up to 24 months for some arms. The study involves scheduled visits for dosing and evaluations, with ongoing data collection to understand treatment effects and safety.
Actively Recruiting
Researchers are evaluating zanidatamab combined with chemotherapy for people with early-stage HER2-positive breast cancer. This Phase 2 trial aims to determine if this combination is safe and effective compared to standard treatments. Participants have newly diagnosed Stage II or III invasive breast cancer confirmed to be HER2-positive, with specific health and organ function requirements. Participants are randomly assigned to one of three groups zanidatamab with paclitaxel, zanidatamab with docetaxel and carboplatin, or trastuzumab and pertuzumab with docetaxel and carboplatin. All drugs are given intravenously before surgery. After completing the neoadjuvant therapy, participants will have a mastectomy or breast conserving surgery as decided by their doctor. During the study, participants will have regular assessments including heart function tests, adverse event monitoring, and evaluations of tumor response up to 8 months. Additional follow-up for safety and survival outcomes extends up to nearly 4 years. Researchers will measure the number of participants achieving complete tumor response, side effects, and long-term survival, while monitoring drug levels and immune reactions.
Actively Recruiting
Researchers are evaluating the use of remibrutinib, a Brutons tyrosine kinase BTK inhibitor, in adults with moderate-to-severe papulopustular rosacea PPR. This Phase 2 study aims to determine if remibrutinib can reduce inflammatory lesions on the face while assessing its safety and tolerability in this condition. The study is randomized, double-blind, and placebo-controlled, involving multiple centers. After a screening period of up to 30 days, during which participants must stop certain rosacea treatments and systemic therapies, eligible adults are randomly assigned to receive either remibrutinib or a matching placebo. This treatment phase lasts 16 weeks, followed by a safety follow-up visit about 30 days after the last dose. Participants take the study drug orally. During the trial, participants undergo evaluations of their facial inflammatory lesions at the start and after 16 weeks of treatment. Researchers track changes in lesion counts and severity using an Investigators Global Assessment scale. Safety and tolerability are monitored throughout the study. Total participation includes screening, treatment, and follow-up lasting several months.
Actively Recruiting
Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of AMO959 combined with lutetium 177Lu vipivotide tetraxetan AAA617 and androgen receptor pathway inhibitors ARPIs in adult men with PSMA-positive metastatic castration resistant prostate cancer mCRPC. This study includes participants who have failed one prior ARPI treatment, with or without previous taxane chemotherapy exposure. The study has two phases Phase Ib focuses on safety and dosing, and Phase II evaluates preliminary efficacy. The study consists of two phases. Phase Ib includes three dose level groups assessing AMO959 alone first, then combined with AAA617 and ARPI abiraterone or enzalutamide. Dose escalation meetings determine the recommended dose for expansion. Phase II randomizes participants into three arms to receive AMO959 with AAA617 and ARPI, AAA617 with ARPI, or other combinations, with treatments given in cycles up to six times every six weeks. Participants will receive study drugs in scheduled cycles and undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, dose adjustments, drug exposure, and biochemical responses such as PSA levels. Safety and treatment effects are tracked up to approximately 24 to 45 months. The study involves multiple visits for treatment and follow-up evaluations, measuring outcomes like progression-free survival, response rates, and quality of life.
Actively Recruiting
Researchers are evaluating treatments for advanced HRD-positive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, and clear cell carcinoma of the ovary in patients who have no residual tumor after primary tumor debulking. This phase II, multicenter, randomized, open-label study compares the recurrence-free survival of patients receiving either 3 cycles of carboplatin plus paclitaxel followed by maintenance therapy with niraparib or 6 cycles of the same chemotherapy plus niraparib maintenance. The study includes patients with specific disease stages FIGO IIIA to IV and uses genetic testing to stratify patients based on tumor characteristics.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a combination of three drugs inavolisib, ribociclib, and fulvestrant, compared to a placebo combined with ribociclib and fulvestrant. This study focuses on participants with advanced breast cancer that is resistant to hormone therapy, specifically those with hormone receptor-positive, HER2-negative breast cancer. The trial is a Phase II, randomized, double-blind study sponsored by Hoffmann-La Roche. Participants are randomly assigned to receive either the triple combination of inavolisib, ribociclib, and fulvestrant, or a placebo with ribociclib and fulvestrant. All medications will be given according to a schedule detailed in the study protocol. The study aims to observe the effects of these treatments over a period of up to approximately two years. During the study, participants will undergo assessments to measure confirmed objective response, progression-free survival, overall survival, and duration of response. Researchers will also monitor clinical benefit, adverse events, and the impact of treatment side effects on daily life using patient-reported questionnaires. Safety and treatment tolerability will be closely observed, with data collected throughout the study duration of up to two years.
Actively Recruiting
Researchers are evaluating the safety and efficacy of GIA632 in adults aged 18 to 99 years with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled Phase 2b study aims to identify the optimal dose of GIA632 to be further studied in a Phase 3 program. The study also includes an extension period to assess longer-term safety and effectiveness. Participants will be randomly assigned to one of several groups receiving either GIA632 or a placebo during a 48-week core treatment period. The study will measure the dose-response relationship of GIA632 and compare its effects with placebo. The extension phase will further evaluate the safety and efficacy over a longer term. During the study, participants will have regular assessments including measurement of facial and total body vitiligo area using the Vitiligo Area Scoring Index VASI at baseline and multiple time points up to 48 weeks. Researchers will also track improvements using the Vitiligo Noticeability Scale. Safety and treatment response will be monitored throughout the study period, which lasts up to approximately four years including follow-up.
1-10 of 190
1